What is the recommended treatment for persistent postural perceptual dizziness (PPPD)?

Treatment of Persistent Postural-Perceptual Dizziness (PPPD)

Treat PPPD with combined selective serotonin reuptake inhibitors (SSRIs) plus structured vestibular rehabilitation therapy (VRT) as first-line therapy, as this combination demonstrates superior outcomes in reducing dizziness severity and anxiety compared to either treatment alone 1.

Primary Treatment Algorithm

First-Line: Combined SSRI + VRT

Start both therapies simultaneously rather than sequentially:

Pharmacotherapy:

• Initiate low-dose SSRI (specific agent not critical; sertraline, escitalopram commonly used)
• Warn patients about initial adverse events (nausea, abdominal distension) occurring in approximately 60% during first 2 weeks, but these resolve by subsequent visits 2
• Continue for minimum 3 months; benefits are maintained up to 3 years 2
• Overall medication adherence rate is 73%, which is acceptable 2

Vestibular Rehabilitation:

• Customized VRT shows superior efficacy compared to virtual reality-based approaches 3
• VRT produces significant improvements across all Dizziness Handicap Inventory (DHI) domains: total score (mean difference 21.84 points), physical (17.92 points), emotional (10.51 points), and functional (15.00 points) 3
• Structure therapy to address the patient's dominant clinical dimension (see below)

Expected Timeline of Improvement

• 3 months: Significant reductions in DHI (from median 40.4 to 8.0), anxiety (GAD-7 from 8.0 to 0.0), and depression (PHQ-9 from 8.0 to 0.0) 4
• 1 year: Approximately 63% of patients achieve clinically meaningful improvement (≥18-point DHI reduction) 2
• Benefits persist through 3 years of follow-up 2

Phenotype-Guided Treatment Weighting

While all patients receive combined SSRI + VRT, adjust the emphasis based on dominant clinical features 5:

Visually-dominant patients:

• Emphasize habituation exercises in visually complex environments
• Progressive exposure to motion-rich visual stimuli

Active motion-postural dominant:

• Focus on dynamic balance retraining
• Graded postural challenges

Affective-hypervigilant dominant:

• Add cognitive behavioral therapy (CBT) to SSRI + VRT
• Address catastrophic thinking and safety behaviors

Migraine-overlap:

• Consider migraine prophylaxis alongside standard PPPD treatment
• Address vestibular migraine triggers

Second-Line Options for Treatment-Resistant Cases

Transcranial Magnetic Stimulation (TMS)

For patients failing first-line therapy after 3 months:

• Target left dorsolateral prefrontal cortex (DLPFC)
• Protocol: 10 Hz, 20 minutes, 10 sessions over 2 weeks 6
• Produces significant reductions in dizziness and anxiety maintained at 3 months 6
• Safe with minimal adverse events

Transcranial Direct Current Stimulation (tDCS)

• Evidence remains limited with small sample sizes 1
• Consider only when TMS unavailable or contraindicated

Critical Clinical Pitfalls

Do NOT use vestibular suppressants (antihistamines like meclizine, benzodiazepines like diazepam):

• No evidence of efficacy for PPPD 7
• These medications interfere with central compensation mechanisms
• May decrease diagnostic sensitivity
• Exception: Short-term use for severe acute nausea only

Recognize the subjective-objective dissociation:

• 88% of PPPD patients have psychiatric comorbidity (anxiety/depression) 4
• Objective balance testing is typically normal despite severe subjective disability 4
• This dissociation is characteristic and should not delay diagnosis or treatment

Address psychiatric comorbidity aggressively:

• Screen all patients with PHQ-9 and GAD-7
• Psychiatric symptoms improve in parallel with dizziness when treated appropriately 4

Structured Diagnostic Explanation is Therapeutic

Provide neurologist-delivered (or specialist-delivered) structured explanation of:

• The functional nature of PPPD
• Maladaptive sensory reweighting mechanisms
• Expected treatment course and timeline
• This explanation itself facilitates treatment engagement and recovery 4

Monitoring and Reassessment

Reassess at 3 months to document:

• DHI score reduction (target ≥18-point improvement)
• Anxiety/depression scores (PHQ-9, GAD-7)
• Treatment adherence and adverse effects

If inadequate response at 3 months:

• Verify diagnosis accuracy (rule out other vestibular or CNS disorders)
• Assess medication adherence (common barrier)
• Consider TMS as adjunctive therapy
• Intensify CBT component if affective symptoms predominate

Important Limitation

Somatosensory hypersensitivity (measured by head-tilt perception gain) does not improve with pharmacotherapy alone 2, suggesting that VRT remains essential even in medication responders to address this persistent sensory processing abnormality.